Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 1, 2012

View Archived Issues

GABAergic compound shows early promise in improving fragile X symptoms

Phase II trial begins for molecular imaging drug for prostate cancer

Amakem begins phase IIa AMA-0076 trial

University of Chicago designs novel anti-staphylococcal agents

Research at the University of Pennsylvania yields new cancer biotherapeutics

Novel AMPK activators disclosed in GSK patent

Seebri Breezhaler approved for COPD maintenance treatment in Japan

New York University presents new PGRN variants for inflammation

Pfizer obtains approval for Tygacil in Japan

Further clinical data reported on cancer vaccine MGN-1601 at ESMO

Neuralstem cleared to study NSI-566 in China

Novel BACE1 inhibitors created at Janssen Pharmaceutica

Phase I data on veliparib in patients with brain metastases reported

Roche presents new antidiabetic compounds

Dainippon Sumitomo Pharma obtains approval for Aimix combination tablets

Ariad completes rolling NDA submission for ponatinib

Novartis obtains Japanese approval for tobramycin

FDA expands approval of Venofer to pediatric patients

Phase III trial of OncoGenex' lead candidate commences in advanced NSCLC

Stem cell gene therapy shows promise in mucopolysaccharidosis IIIA model

Vital Therapies closes first stage of financing to fund phase III program for Elad

Osiris Therapeutics regains rights to Prochymal and Chondrogen

StemCells gives update on phase I/II chronic spinal cord injury study

Teva acquires Huntexil development program rights from NeuroSearch

Zosyn receives new indication approvals in Japan

Lotriga approved in Japan for the treatment of hyperlipidemia

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...